Precigen Terminates License Agreement With Alaunos Therapeutics

Dow Jones10-11

By Adam L. Cataldo

Precigen terminated a licensing agreement with Alaunos Therapeutics, according to a Securities and Exchange Commission filing on Thursday.

The Germantown, Md. biotechnology company said that on Oct. 4 it terminated the amended and restated license agreement it entered into with Alaunos, regained all rights it had licensed and that Alaunos retained no rights to utilize any of its technology.

Precigen said when agreement was amended in April 2023 that the move would bolster its portfolio and broaden strategic opportunities, according to a press release on the company's website. It also said the company had regained exclusive rights to its IL-12 gene therapy.

Write to Adam Cataldo at adam.cataldo@wsj.com.

(END) Dow Jones Newswires

October 10, 2024 18:31 ET (22:31 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474757705?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-11 06:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2474757705","market":"sg","top_or_hot":-1,"title":"Precigen Terminates License Agreement With Alaunos Therapeutics","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Adam L. Cataldo \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/PGEN\">Precigen</a> terminated a licensing agreement with <a href=\"https://laohu8.com/S/TCRT\">Alaunos Therapeutics</a>, according to a Securities and Exchange Commission filing on Thursday. \n</p>\n<p>\n  The Germantown, Md. biotechnology company said that on Oct. 4 it terminated the amended and restated license agreement it entered into with Alaunos, regained all rights it had licensed and that Alaunos retained no rights to utilize any of its technology. \n</p>\n<p>\n  Precigen said when agreement was amended in April 2023 that the move would bolster its portfolio and broaden strategic opportunities, according to a press release on the company's website. It also said the company had regained exclusive rights to its IL-12 gene therapy. \n</p>\n<p>\n  Write to Adam Cataldo at adam.cataldo@wsj.com. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 10, 2024 18:31 ET (22:31 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Precigen Terminates License Agreement With Alaunos Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrecigen Terminates License Agreement With Alaunos Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-11 06:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Adam L. Cataldo \n\n\nPrecigen terminated a licensing agreement with Alaunos Therapeutics, according to a Securities and Exchange Commission filing on Thursday. \n\n\n  The Germantown, Md. biotechnology ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2474757705","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474757705","pubTimestamp":1728599460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Precigen terminated a licensing agreement with Alaunos Therapeutics, according to a Securities and Exchange Commission filing on Thursday.The Germantown, Md. biotechnology company said that on Oct. 4 it terminated the amended and restated license agreement it entered into with Alaunos, regained all rights it had licensed and that Alaunos retained no rights to utilize any of its technology.Precigen said when agreement was amended in April 2023 that the move would bolster its portfolio and broaden strategic opportunities, according to a press release on the company's website. It also said the company had regained exclusive rights to its IL-12 gene therapy.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TCRT":"Alaunos Therapeutics","PGEN":"Precigen"},"translate_title":"Precigen终止与Alaunos Therapeutics的许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PGEN":1,"TCRT":1},"content_text":"By Adam L. Cataldo \n\n\nPrecigen terminated a licensing agreement with Alaunos Therapeutics, according to a Securities and Exchange Commission filing on Thursday. \n\n\n  The Germantown, Md. biotechnology company said that on Oct. 4 it terminated the amended and restated license agreement it entered into with Alaunos, regained all rights it had licensed and that Alaunos retained no rights to utilize any of its technology. \n\n\n  Precigen said when agreement was amended in April 2023 that the move would bolster its portfolio and broaden strategic opportunities, according to a press release on the company's website. It also said the company had regained exclusive rights to its IL-12 gene therapy. \n\n\n  Write to Adam Cataldo at adam.cataldo@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 10, 2024 18:31 ET (22:31 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474757705"}